Bio Rad Laboratories, Inc. (NYSE:BIO) Q4 2021 Earnings Conference Call February 10, 2022 6:00 PM ET Company Participants Edward Chung - VP, IR Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Simon May - EVP & President, Life Science Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citigroup Daniel Leonard - Wells Fargo Securities Jack Meehan - Nephron Research Operator Good evening. Thank you for attending today's Bio-Rad Laborat ...

Title of Each ClassTrading Symbols Name of Each Exchange on Which Registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-792 ...

Financial Data and Key Metrics Changes - Net sales for Q3 2021 were $747 million, a 15.4% increase from $647.3 million in Q3 2020, with a currency-neutral growth of 13.8% [10] - Reported gross margin improved to 58.6% from 56.7% in Q3 2020, driven by settlement payments and productivity initiatives [14] - Reported net income for Q3 was $3.928 billion, with diluted earnings per share of $129.96, significantly influenced by changes in the valuation of equity securities [16] Business Line Data and Key Metrics Changes - Life Science Group sales increased to $373.5 million in Q3 2021 from $324 million in Q3 2020, a 15.3% increase on a reported basis [11] - Clinical Diagnostics Group sales rose to $372.2 million in Q3 2021 from $322.2 million in Q3 2020, marking a 15.5% increase on a reported basis [13] - Excluding COVID-related sales, the underlying Life Science business grew 4.1% on a currency-neutral basis [11] Market Data and Key Metrics Changes - Strong currency-neutral growth was observed in the Americas and Asia, while Europe experienced a slight decline due to tough year-over-year comparisons [11] - COVID-19-related sales were estimated at $57 million for the quarter, with expectations for a sequential decline in COVID-related demand in Q4 [11][8] Company Strategy and Development Direction - The company is focusing on addressing supply chain constraints and has implemented careful management to balance supply and demand [7] - The acquisition of Dropworks for approximately $125 million is expected to enhance Bio-Rad's entry into the lower-end segment of the digital PCR business [20] Management's Comments on Operating Environment and Future Outlook - Management anticipates continued supply chain constraints into 2022, impacting customer delivery timing [22] - Full-year 2021 non-GAAP currency-neutral revenue growth is now guided to be between 12% and 13%, up from prior guidance [22] Other Important Information - The company introduced a mandatory vaccination requirement for all U.S. employees, reflecting its commitment to employee safety [8] - The effective tax rate for Q3 2021 was 21.8%, slightly lower than 21.9% in Q3 2020, influenced by unrealized gains in equity securities [16] Q&A Session Summary Question: Can you elaborate on the margin guidance in the fourth quarter? - Management clarified that operating margin guidance is slightly higher than previous quarters, with increased operating expenses expected [25][27] Question: What is the progress on restructuring initiatives announced in February? - Management reported that progress is on track, with most performance enhancements expected in 2023 [28] Question: Can you discuss supply and demand issues in more detail? - Management indicated that supply chain challenges are broad and affect various components, with expectations for these issues to persist into 2022 [30][31] Question: How is the diagnostics market in China performing? - Management noted that there has been no significant negative impact from centralized purchasing initiatives in China, and the company is monitoring the situation [38][39] Question: What is the growth outlook for the Life Science business? - Management expressed optimism about sustained double-digit growth in the Droplet Digital PCR portfolio, particularly in the biopharma market [34][42] Question: Can you provide insights on the Dropworks business? - Management refrained from providing detailed financials but emphasized that Dropworks is well-suited for cost-sensitive segments in the digital PCR market [49][50]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-138 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2021 Earnings Conference Call July 29, 2021 6:00 PM ET Company Participants Edward Chung - Head of IR Norman Schwartz - CEO Ilan Daskal - EVP and CFO Andrew Last - EVP and COO Annette Tumolo - President, Life Science Group Dara Wright - President, Clinical Diagnostics Group Conference Call Participants Patrick Donnelly - Citi Brandon Couillard - Jefferies Dan Leonard - Wells Fargo Jack Meehan - Nephron Research Operator Good afternoon, ladies and gentlemen, and welco ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from______________to __________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 94-1381833 ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2021 Earnings Conference Call April 29, 2021 6:00 PM ET Company Participants Ronald Hutton - VP & Treasurer Ilan Daskal - EVP & CFO Andrew Last - EVP & COO Norman Schwartz - Chairman, CEO & President Annette Tumolo - EVP & President, Life Science Group Dara Wright - EVP & President, Clinical Diagnostics Group Conference Call Participants Brandon Couillard - Jefferies Daniel Leonard - Wells Fargo Securities Patrick Donnelly - Citigroup Nisarg Shah - Nephron Operator L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or Title of each class Trading Symbol(s) Name of each exchange on which registered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange Class B Common Stock, Par Value $0.0001 per share BIOb New York Stock Exchange ☐ TRANSITION REPORT PURSUANT TO SECTION 13 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________________ to _________________________________ Commission file number 1-7928 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its ch ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2020 Earnings Conference Call February 11, 2021 6:00 PM ET Corporate Participants Ron Hutton - Treasurer Norman Schwartz - Chief Executive Officer Ilan Daskal - Executive Vice President and Chief Financial Officer Andy Last - Executive Vice President and Chief Operating Officer Annette Tumolo - President of the Life Science Group Dara Wright - President of the Clinical Diagnostics Group Conference Call Participants Dan Leonard - Wells Fargo Brandon Couillard - Jeffe ...